Advanced-accelerator-applications
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Precision medicine approach combining a targeting ligand with a radioisotope to selectively damage cancer cells while limiting impact on healthy cells; a 'see it, treat it' methodology for diagnosis and treatment; capability to combine different isotopes and ligands to target various cancer types.
Description Brand's website · 2026-10-04
Advanced Accelerator Applications, an entity within Novartis, develops radioligand therapies (RLTs), a novel precision medicine approach for cancer care that combines a targeting compound with a radioisotope to find, diagnose, and treat cancer cells throughout the body while minimizing harm to healthy cells.
Offerings
Core capabilities Brand's website · 2026-10-04
- Radioligand Therapies (RLTs) for cancer
- used for both diagnostic imaging and therapeutic applications
- targeting various cancers including prostate and neuroendocrine tumors.
Pricing Brand's website · 2026-10-04
Not explicitly stated, but products are custom-produced on an 'as ordered' basis for individual patients, suggesting a specialized B2B pricing model for healthcare providers.
Audience
Target industry Brand's website · 2026-10-04
Healthcare professionals (HCPs), hospitals, clinics, and patients with cancer.
Is this your business?
The information above is publicly sourced — assembled by Optimly from Advanced-accelerator-applications's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Advanced-accelerator-applications across the index.
Claim Advanced-accelerator-applications — free →Page last updated 2026-10-17.